CJC-1295/Ipamorelin 10 mg Blend Dosing

A 10 mg CJC-1295/ipamorelin blend vial typically contains 5 mg of each peptide (10 mg total). When community forums cite "200 mcg" as a common dose, they mean 200 mcg of the combined blend per injection, not 200 mcg of each peptide separately. The confusion is reasonable: vendor labels rarely spell this out, and peptide-reconstitution calculators sometimes default to single-compound math. Here is how the arithmetic actually works, what the published literature says about each peptide, and what it does not say about the combination.

What is in a 10 mg blend vial

Grey-market "CJC-1295/ipamorelin blend" vials are not standardised products. There is no pharmacopoeia monograph, no FDA-approved label, and no EMA marketing authorisation for either peptide alone or in combination^[1][2]. That said, the most common configuration sold online is 5 mg CJC-1295 (usually the no-DAC version, also called MOD-GRF 1-29) plus 5 mg ipamorelin lyophilised together in one vial, labelled as "10 mg blend." Some vendors sell 5 mg/5 mg blends labelled as "5 mg" (listing only one peptide's weight). Always check the certificate of analysis, if one exists, for the actual content per vial.

Reconstitution math, step by step

The concentration of your reconstituted solution depends on two numbers: the total peptide mass in the vial (in micrograms) and the volume of bacteriostatic water you add (in millilitres). Everything else follows from division.

Converting the vial to a working concentration

A 10 mg vial contains 10,000 mcg of total peptide. If you add 2 mL of bacteriostatic water, the concentration is 10,000 mcg / 2 mL = 5,000 mcg per mL. If you add 3 mL, the concentration is 10,000 mcg / 3 mL = approximately 3,333 mcg per mL.

From concentration to syringe units

Standard U-100 insulin syringes are calibrated so that 100 "units" on the barrel equals 1 mL. That means each tick mark (1 unit) equals 0.01 mL. Once you know your concentration in mcg per mL, dividing the desired dose (in mcg) by that concentration gives you the volume in mL, which you convert to syringe units by multiplying by 100.

Worked example with 3 mL of bacteriostatic water added to a 10 mg vial: concentration = 3,333 mcg/mL. For a 200 mcg dose: 200 / 3,333 = 0.06 mL = 6 units on a U-100 syringe. For the same vial reconstituted with 2 mL instead: concentration = 5,000 mcg/mL. For a 200 mcg dose: 200 / 5,000 = 0.04 mL = 4 units.

This is where the "6 units vs 12 units" confusion in community posts comes from. The number of syringe units depends entirely on how much water you added. Two people using the same vial and targeting the same 200 mcg dose will draw different volumes if they reconstituted with different amounts of water. Neither is wrong; they are measuring the same mass of peptide in different concentrations.

Why the "200 mcg" figure circulates

Neither CJC-1295 nor ipamorelin has a regulatory-approved dose for any human indication. The 200 mcg figure that appears across forums and vendor sites is not from a clinical guideline. It traces loosely to the dose range explored in the only published human pharmacokinetic study of CJC-1295, by Teichman et al. in 2006, which tested single and repeated subcutaneous doses of 30 to 60 mcg/kg in healthy adults^[3]. For a 75 kg person, 30 mcg/kg would be 2,250 mcg (not 200 mcg), so the community dose is well below the studied range. The number appears to have been carried forward through forum convention rather than through any clinical reasoning.

For ipamorelin, the published human pharmacokinetic data is even thinner. Its original characterisation by Raun et al. in 1998 established its selectivity for growth-hormone release over ACTH and cortisol in animal models^[4], but no published Phase 2 or Phase 3 efficacy trial in humans has defined a therapeutic dose range. The FDA's Pharmacy Compounding Advisory Committee reviewed ipamorelin in October 2024 and did not recommend it for inclusion on the 503A bulks list^[5].

CJC-1295 with DAC vs without DAC (MOD-GRF 1-29)

The "CJC-1295" in most blend vials is MOD-GRF(1-29), the version without the drug-affinity complex (DAC). The DAC version binds covalently to serum albumin after injection, extending the half-life to roughly 6 to 8 days^[6]. MOD-GRF(1-29) lacks this albumin-binding modification and has a much shorter half-life. The two are different molecules with different pharmacokinetics, and the reconstitution math is the same for both, but the dosing frequency community users report differs. Vendor labels do not always specify which version is in the vial. If the label says only "CJC-1295" without mentioning DAC, it is usually the no-DAC (MOD-GRF) form, but you cannot be certain without third-party testing.

What the published literature does not tell us

There is no published clinical trial testing the CJC-1295/ipamorelin combination in humans at any dose. A 2026 review of injectable peptide therapy in sports medicine noted that information about "indications, dosing, frequency, and duration of treatment remains unknown" for growth-hormone secretagogue combinations^[7]. We do not know the optimal ratio of the two peptides, whether combining them in a single vial affects stability or bioavailability, or what adverse-event profile the combination produces at any dose. Forum-sourced dosing protocols are empirical guesses, not evidence-based recommendations.

We also do not know the purity, identity, or sterility of grey-market blend vials. Independent analyses of research-chemical peptide products have found mislabelling and contamination. A dosing calculation is only as reliable as the label it starts from.

A note on safety

Both CJC-1295 and ipamorelin are unapproved substances with no marketing authorisation from the FDA, EMA, MHRA, or any national medicines agency tracked on this site. They are prohibited by WADA in sport. The decision to use them belongs with you and a clinician who knows your medical history. If you are considering either peptide, read the full profiles on the CJC-1295 and ipamorelin pages for the regulatory and evidence picture, and talk to your doctor before making any changes.